ImmunoForge Seeks Global Partners for FDA-Cleared Rare Disease Therapies at JPM 2026
核心洞察
ImmunoForge (搜索) will conduct strategic partnering meetings during the J.P. Morgan Healthcare Conference 2026 to out-license Phase 2 assets PF1801 and PF1804 for rare muscle diseases.
The company's lead candidate PF1801 (froniglutide) has received FDA Orphan Drug Designation for polymyositis (搜索), dermatomyositis (搜索), and Duchenne muscular dystrophy (搜索) and is currently in Phase 2 trials in South Korea.
Both PF1801 and PF1804 have secured FDA Phase 2 IND clearance, positioning them for immediate U.S. clinical launch by global pharmaceutical partners.
ImmunoForge (搜索) Co., Ltd., a clinical-stage biopharmaceutical company specializing in rare diseases, announced it will conduct strategic one-on-one meetings with global pharmaceutical companies and investors during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. The Seoul-based company, led by Co-CEOs Sung-Min Ahn and Kiho Chang, is focusing on securing global out-licensing partnerships for its Phase 2 assets rather than delivering formal stage presentations.
FDA-Cleared Assets Ready for U.S. Market Entry
The company's primary objective centers on finding strategic partners capable of spearheading U.S. clinical trials for its key Phase 2 assets. PF1801 (froniglutide), ImmunoForge (搜索)'s lead candidate, is currently undergoing Phase 2 clinical trials for polymyositis (搜索) and dermatomyositis (搜索) in South Korea. The U.S. FDA has granted Orphan Drug Designation to PF1801 for polymyositis, dermatomyositis, and Duchenne muscular dystrophy (搜索), recognizing its therapeutic potential for these rare conditions.
PF1804 (pemziviptadil), targeting DMD-associated cardiomyopathy, has also received FDA IND approval for Phase 2 studies and stands ready for clinical execution with strategic partners. Both assets have secured FDA Phase 2 IND clearance, positioning them for immediate U.S. clinical launch by global partners.
Proprietary ELP Platform Technology
ImmunoForge (搜索) leverages its proprietary long-acting Elastin-Like Polypeptide (搜索) (ELP (搜索)) platform technology to extend the half-life of peptide-based drugs, enabling weekly or monthly dosing schedules. The company has developed two distinct ELP platforms: a monthly long-acting version that allows peptide conjugation and protein fusion, and a blood-brain barrier penetrating variant designed to create monthly CNS drugs through BBB shuttle technology.
Expanding Pipeline and Licensing Strategy
Beyond its lead Phase 2 assets, ImmunoForge (搜索) is advancing additional candidates including PF1807 for sarcopenia (搜索), a monthly therapy based on use patents for preventing and treating myositis and sarcopenia. The company's KF1601 for chronic myeloid leukemia (搜索) has already been licensed domestically ahead of a Phase 1 launch in Korea next year, while global licensing rights excluding Korea remain available for international partners.
"Our goal for JPM 2026 week is to meet with potential partners who can leverage our FDA-cleared INDs to rapidly bring these therapies to the U.S. market," said a representative from ImmunoForge (搜索). "As a lean biotech, we have focused on de-risking our assets through regulatory clearances; we are now looking for the right global collaborators to take these programs through the next phase of clinical development and to the commercial markets."
Strategic Partnership Models
The company is pursuing multiple partnership models beyond traditional licensing deals with global pharmaceutical companies, including NewCo models led by investors. ImmunoForge (搜索) aims to expand its development capabilities by introducing its diverse pipeline to global companies, encompassing both its established long-acting ELP (搜索) platform and the newly developed BBB-penetrating ELP platform technology.
ImmunoForge (搜索)'s early-stage pipeline includes PF1802 for CNS applications, PF1803 for osteoarthritis, and KF1601 for oncology. The company is actively seeking global co-development and licensing partnerships for both its pipeline assets and ELP (搜索) platform technology to accelerate delivery of these therapies to patients worldwide.